Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED (China) ( (HK:0013) ) has shared an update.
HUTCHMED reported 2025 net income of $456.9 million and total in‑market sales of $524.7 million, marking its third consecutive year of profit and supported by a $1.4 billion year‑end cash balance and a significant divestment gain. Growth was driven by ex‑China expansion of FRUZAQLA, improving second‑half sales in China after a commercial reorganization, and milestone income from AstraZeneca following a new China indication for ORPATHYS.
The company advanced its Antibody‑Targeted Therapy Conjugate platform, moving its first two candidates into clinical trials and planning a third Phase I start by year‑end, while actively seeking partnerships with multinational pharma to accelerate global development. Late‑stage programs delivered positive Phase II and III data across multiple indications, leading to regulatory filings for sovleplenib and further label expansions for fruquintinib and savolitinib, positioning HUTCHMED for a stronger pipeline‑driven revenue base and reinforcing its role as an emerging global oncology player.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies, with a strong presence in oncology. Its key products include fruquintinib, marketed as FRUZAQLA globally and ELUNATE in China, the MET inhibitor savolitinib (ORPATHYS), and other late-stage assets targeting hematological and solid tumors, with an increasing emphasis on global markets beyond China.
For detailed information about 0013 stock, go to TipRanks’ Stock Analysis page.